Key takeaways
- • Trial: REWIND (NCT01394952) — Phase 3, 9,901 participants over 280 weeks.
- • Drug studied: Trulicity (Dulaglutide) — FDA-approved branded product.
- • Primary endpoint: Time to first major adverse cardiovascular event in adults with type 2 diabetes
- • Key result: 12% relative risk reduction in MACE on dulaglutide 1.5mg vs placebo (HR 0.88, 95% CI 0.79-0.99)
- • Published: The Lancet, 2019.
Study design
REWIND was a phase 3 randomized controlled trial enrolling 9,901 participants over 280 weeks. The trial studied Trulicity (Dulaglutide) for cardiovascular outcomes and was published in The Lancet in 2019.
Primary endpoint
Time to first major adverse cardiovascular event in adults with type 2 diabetes
Key results
| Measure | Value |
|---|---|
| Headline result | 12% relative risk reduction in MACE on dulaglutide 1.5mg vs placebo (HR 0.88, 95% CI 0.79-0.99) |
| Participants | 9,901 |
| Duration | 280 weeks |
| Phase | Phase 3 |
Citation
REWIND. Published in The Lancet, 2019.
GLP1Zoom did not conduct this trial. We summarize published primary literature. For verbatim methods and full results, consult the primary publication and the ClinicalTrials.gov registry record.
Related
- Trulicity drug page — pricing, FDA status, side effects, alternatives
- All dulaglutide trials
- GLP-1 clinical trials database
Other Trulicity trials
- AWARD-7 — HbA1c reduction 1
Important: This trial was conducted on the FDA-approved branded product Trulicity. Compounded versions of Dulaglutide have NOT been studied in equivalent randomized controlled trials, and their efficacy and safety profile may differ.
GLP1Zoom is an affiliate-only comparator. We cite published trials; we do not conduct them. This page is informational and is not a substitute for personalized medical advice — always confirm any treatment decision with your prescribing clinician. Full disclaimer.